ProMIS Neurosciences shares are trading higher after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for AD, PMN310, and additional studies that further characterize a computationally-derived AD vaccine at AAIC 2023.
Portfolio Pulse from Benzinga Newsdesk
ProMIS Neurosciences presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's Disease (AD), PMN310, and additional studies that further characterize a computationally-derived AD vaccine at AAIC 2023. This has led to a rise in the company's share prices.
July 17, 2023 | 2:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProMIS Neurosciences' shares are trading higher after the company presented positive preclinical data for its lead AD candidate, PMN310.
The positive preclinical data for PMN310, ProMIS Neurosciences' lead candidate for Alzheimer's Disease, has increased investor confidence in the company's potential, leading to a rise in its share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100